Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder
摘要:
A series of substituted glutaramides were synthesised using Candoxatrilat 1 as a lead and evaluated for potency against neutral endopeptidase (NEP) as a potential treatment for female sexual arousal disorder (FSAD). In this paper, we describe studies in which we were able to increase NEP activity substantially over the levels reported for previous compounds from this programme by appropriate substitution in both the P'(1) and P'(2) regions. Optimisation led to the 4-chlorophenpropylamide S-30 which was selected as a candidate for further study. (c) 2006 Elsevier Ltd. All rights reserved.
[EN] QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES [FR] DERIVES DE QUINOLINE-2-ONE PERMETTANT DE TRAITER DES MALADIES DES VOIES RESPIRATOIRES
[EN] DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA<br/>[FR] INHIBITEURS DE ROR-GAMMA À BASE DE DIHYDROPYRROLOPYRIDINE
申请人:VITAE PHARMACEUTICALS INC
公开号:WO2015116904A1
公开(公告)日:2015-08-06
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS
申请人:Ackermann Jean
公开号:US20080103183A1
公开(公告)日:2008-05-01
Compounds of formula
as well as pharmaceutically acceptable salts and esters thereof, wherein R
1
to R
6
have the significance given in claim
1
can be used in the form of pharmaceutical compositions.
A hydantoin derivative represented by formula (I):
wherein the all symbols are defined in the disclosure. The hydantoin derivative has an inhibitory activity on metalloprotease and hence is useful as analgesic and cardiovascular drug.
The present invention relates to the use of neutral endopeptidase inhibitors (NEPi) and a combination of NEPi and phosphodiesterase type 5 (PDE5) inhibitor for the treatment of male sexual dysfunction, in particular MED.
[EN] CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE<br/>[FR] DERIVES DE GLUTARAMIDE SUBSTITUES PAR DU CYCLOPENTYL UTILISES COMME INHIBITEURS DE L'ENDOPEPTIDASE NEUTRE
申请人:PFIZER LTD
公开号:WO2002002513A1
公开(公告)日:2002-01-10
The invention provides compounds of formula I wherein R1 is optionally substituted C¿1?-6alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl; n is 0, 1 or 2; and Y is -NR?18S(O)¿uR19 or a group shown below.